<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="47694">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02485301</url>
  </required_header>
  <id_info>
    <org_study_id>202091</org_study_id>
    <nct_id>NCT02485301</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Adults</brief_title>
  <official_title>Safety and Immunogenicity Study of GSK Biologicals' Investigational Recombinant Chimpanzee Adenovirus Type 3-vectored Ebola Zaire Vaccine (GSK3390107A) in Adults in Africa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and immunogenicity of the investigational
      ChAd3-EBO-Z vaccine administered to approximately 3 000 adults in Africa as a single IM dose
      Considering the risk of exposure to Ebola and the potential (based on animal data) for the
      investigational ChAd3-EBO-Z vaccine to afford at least partial protection, all subjects in
      the study will receive the investigational ChAd3-EBO-Z vaccine. The subjects in the Group
      EBO-Z will receive the vaccine at Day 0 of the study, whereas the subjects in the Group
      Placebo/ EBO-Z will receive a placebo at Day 0 (as a control) and will receive the
      investigational ChAd3-EBO-Z vaccine at Month 6, provided that no safety concerns are raised.
      In addition, vaccinating all subjects in the study with the investigational ChAd3 EBO Z
      vaccine will allow an increase of the safety database of the investigational vaccine. In
      case the geographic range of Ebola virus Zaire (EBOV) transmission expands to encompass any
      of the regions where this trial is conducted, earlier administration of the investigational
      ChAd3-EBO-Z vaccine to the subjects in the Group Placebo/ EBO-Z will be considered in that
      region.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Participant, Care Provider, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of each solicited local and general AE</measure>
    <time_frame>Up to Day 7 after each vaccination (i.e. the day of vaccination and 6 subsequent days), in a sub cohort of 750 subjects per group.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of any unsolicited AE</measure>
    <time_frame>Up to Day 30 after each vaccination (i.e. the day of vaccination and 29 subsequent days), in a sub-cohort of 750 subjects per group.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of any SAE, in all subjects, in both groups</measure>
    <time_frame>From Day 0 to study end at Month 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of clinical symptoms of thrombocytopenia (AE of specific interest)</measure>
    <time_frame>Up to Day 7 after vaccination at Day 0 (i.e. Day 0 up to Day 6).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of haematological (complete blood count [CBC], including differential count and platelet count)</measure>
    <time_frame>At Screening (Day 0)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of haematological (complete blood count [CBC], including differential count and platelet count)</measure>
    <time_frame>At Day 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of haematological (complete blood count [CBC], including differential count and platelet count)</measure>
    <time_frame>At Day 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of haematological (complete blood count [CBC], including differential count and platelet count)</measure>
    <time_frame>At Day 30</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of haematological (complete blood count [CBC], including differential count and platelet count)</measure>
    <time_frame>At Month 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of haematological (complete blood count [CBC], including differential count and platelet count)</measure>
    <time_frame>At Month 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of haematological (complete blood count [CBC], including differential count and platelet count)</measure>
    <time_frame>At Month 6 + 6 days in a sub cohort of 750 subjects in the Group Placebo/ EBO-Z.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of haematological (complete blood count [CBC], including differential count and platelet count)</measure>
    <time_frame>At Month 6 + 30 days in a sub cohort of 750 subjects in the Group Placebo/ EBO-Z.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of biochemical (alanine aminotransferase [ALT], creatinine) laboratory abnormalities</measure>
    <time_frame>At Screening (Day 0)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of biochemical (alanine aminotransferase [ALT], creatinine) laboratory abnormalities</measure>
    <time_frame>At Day 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of biochemical (alanine aminotransferase [ALT], creatinine) laboratory abnormalities</measure>
    <time_frame>At Day 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of biochemical (alanine aminotransferase [ALT], creatinine) laboratory abnormalities</measure>
    <time_frame>At Month 30</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of biochemical (alanine aminotransferase [ALT], creatinine) laboratory abnormalities</measure>
    <time_frame>At Month 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of biochemical (alanine aminotransferase [ALT], creatinine) laboratory abnormalities</measure>
    <time_frame>At Month 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of biochemical (alanine aminotransferase [ALT], creatinine) laboratory abnormalities</measure>
    <time_frame>At Month 6 + 6 days in a sub cohort of 750 subjects in the Group Placebo/ EBO-Z.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of biochemical (alanine aminotransferase [ALT], creatinine) laboratory abnormalities</measure>
    <time_frame>At Month 6 + 30 days in a sub cohort of 750 subjects in the Group Placebo/ EBO-Z.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-GP EBOV antibody titres, as measured by enzyme-linked immunosorbent assay (ELISA)</measure>
    <time_frame>At Day 0 and Day 30, in a sub-cohort of 750 subjects per group. At Month 6 and Month 6 + 30 days, in a sub-cohort of 750 subjects in the Group Placebo/ EBO-Z.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3024</enrollment>
  <condition>Virus Diseases</condition>
  <arm_group>
    <arm_group_label>Group EBO-Z</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subjects in the Group EBO-Z will receive the vaccine at Day 0 of the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group Placebo/ EBO-Z</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The subjects in the Group Placebo/ EBO-Z will receive a placebo at Day 0 (as a control) and will receive the investigational ChAd3-EBO-Z vaccine at Month 6</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GlaxoSmithKline (GSK) Biologicals' investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (ChAd3-EBO-Z) (GSK3390107A)</intervention_name>
    <description>A single dose administrated intramuscular</description>
    <arm_group_label>Group Placebo/ EBO-Z</arm_group_label>
    <arm_group_label>Group EBO-Z</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A single dose administrated intramuscular</description>
    <arm_group_label>Group Placebo/ EBO-Z</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who, in the opinion of the Investigator, can and will comply with the
             requirements of the protocol (e.g. capability of or availability for Diary Card
             completion, return for follow-up visits, availability for clinical follow-up
             throughout the study period).

          -  Written/ thumb printed informed consent obtained from the subject prior to performing
             any study specific procedure or written/ thumb printed informed consent obtained from
             the subject's parent(s)/ legally acceptable representative(s) (LAR[s]) and written/
             thumb printed informed assent obtained from the subject, for minor subjects. This
             will only be applicable for countries where the legal age of majority is â‰¥ 21 years.

          -  A male or female aged 18 years of age or older at the time of Screening.

          -  Healthy subjects as per Investigator judgement, as established by medical history,
             clinical examination and haematology/ biochemistry laboratory parameters screening
             before entering into the study.

          -  Female subjects of non-childbearing potential may be enrolled in the study.

          -  Non-childbearing potential is defined as pre-menarche, current tubal ligation,
             hysterectomy, ovariectomy or post-menopause.

          -  Female subjects of childbearing potential may be enrolled in the study, if the
             subject:

          -  has practiced adequate contraception for 30 days prior to the Day 0 visit, and

          -  has a negative pregnancy test at the Day 0 visit, and

          -  has agreed to continue adequate contraception until 30 days after the Month 6 visit.

        Exclusion Criteria:

          -  Use of any investigational or non-registered product (drug or vaccine) other than the
             study vaccine during the period starting 30 days before the Day 0 visit, or planned
             use during the study period.

          -  Previous vaccination with an investigational EBOV or Marburg vaccine, or previous
             vaccination with a chimpanzee adenoviral vectored investigational vaccine.

          -  Known prior EBOV or SUDV disease.

          -  Travel to a country affected by the EBOV epidemic or direct contact with a person
             with EVD within 21 days prior to the Day 0 visit.

          -  History of any reaction or hypersensitivity (such as anaphylaxis, urticaria [hives],
             respiratory difficulty, angioedema, or abdominal pain) likely to be exacerbated by
             any component of the study vaccine.

          -  Planned administration/ administration of a vaccine not foreseen by the study
             protocol in the period starting 30 days before and ending 30 days after each
             vaccination visit.

          -  Serious acute or chronic illness determined by medical history and clinical
             examination including, but not limited to:

               -  Clinically significant immunosuppressive or immunodeficient condition (e.g.
                  clinical acquired immune deficiency syndrome [AIDS]).

               -  Any clinically significant haematological (CBC, including differential count and
                  platelet count) or biochemical (ALT, creatinine) laboratory abnormality.

               -  Any chronic illness with recent signs of exacerbation, or imposing a change in
                  the chronic treatment regimen, within 3 months prior to the Day 0 visit.

               -  Any unstable chronic medical condition (e.g. uncontrolled asthma).

          -  Pregnant female.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bamenda</city>
        <country>Cameroon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Yaounde</city>
        <country>Cameroon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bamako</city>
        <country>Mali</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Abuja</city>
        <country>Nigeria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dakar</city>
        <country>Senegal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Cameroon</country>
    <country>Mali</country>
    <country>Nigeria</country>
    <country>Senegal</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 24, 2017</lastchanged_date>
  <firstreceived_date>June 18, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Protection against Ebola Zaire virus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
